Calling Type 2 diabetes “100% genetic” defies foundational metabolic science and meta-analytic evidence. Twin and polygenic risk score data consistently demonstrate a complex gene-environment interaction, with lifestyle drivers being the primary determinant of phenotypic expression. If it were 100% genetic, monozygotic concordance would be absolute…yet large epidemiological cohorts tracked by the International Diabetes Federation and the European Association for the Study of Diabetes prove otherwise. Stop propagating absolutes that distort modern etiology.

Protein is elemental for life.

Your HOMA-IR is nothing more than a 7:00 AM snapshot of your liver at rest, so avoid reading it like a life sentence. Most men get a 2.4 back, panic, and immediately strip away every carbohydrate in sight. That isn't a sound strategy...thats just reactionary and it misses the biological reality of what’s happening inside your body. Here is the truth about the math, the metabolic machinery and why you don't need to fear real food: 1. It measures your liver at rest, not your capacity to burn carbs.HOMA-IR measures how much fasting insulin your liver requires to keep overnight glucose stable. It gives you insight into resting hepatic gluconeogenesis, but it tells you almost nothing about how efficiently your muscle mitochondria handle clean fuel after a workout. 2. Biological noise lies.A single HOMA-IR draw can swing by roughly 32% day-to-day. Poor sleep quality, elevated morning cortisol, or simple lab variance can falsely make a healthy, high-performing man look insulin resistant on a single morning. 3. Cutting carbs hides the signal and it doesn't fix the engine. Eliminating carbohydrates drops fasting insulin, so your score looks "better" on paper. But turning off the smoke alarm doesn't put out the fire. Extreme restriction often induces adaptive insulin resistance, elevates stress hormones, and impairs thyroid conversion (free T3) compromising your energy, recovery and long-term metabolic elasticity. 4. The reference targets: • Under 1.0: Optimal metabolic efficiency. • 1.0 – 2.0: The gray zone, time to look closer at the variables. • Over 2.0: An underlying driver exists, identify the mechanism, please don't guess. How to audit your data before making radical changes: • Standardize: 10–12 hr fast, draw between 7–9 AM, no heavy training or alcohol for 48 hrs, and prioritized sleep. • Cross-examine: Pair it with C-peptide, TG/HDL ratio, hsCRP, and Fructosamine. • Test real-world clearance: Run a home glucose curve with 75g of clean carbs (finger-prick at 0, 30, 60, 90, and 120 mins). You want to see efficient clearance back to baseline within two hours. Mastering your metabolic health isn't about fear or extreme elimination, it is really about objective data, understanding the underlying mechanism and building a resilient, adaptable biological system. So go ahead and test with precision, identify the true bottleneck and humbly aim to fix the root cause. LAVV

Interesting

Running and Your Joints: What the Evidence Actually Says The question every runner eventually asks At some point, usually on a morning when the knees feel a little louder than they should, every runner hears the same warning from a relative, a colleague, or a physician who has not read the literature in a while: you are wearing out your joints. The image is intuitive, almost mechanical. A hinge that opens and closes ten thousand times a day must wear faster than one that stays shut. It is also, as far as the human evidence can tell us, mostly wrong, and the paper I want to walk you through is one of the clearest attempts to measure why. In 2017, a group of orthopaedic surgeons and a biostatistician from Barcelona, Gothenburg, Pittsburgh, Duke and McMaster published a systematic review and meta-analysis in the Journal of Orthopaedic and Sports Physical Therapy. They set out to answer a narrow question with as much of the available data as they could gather: is running associated with osteoarthritis of the hip and knee, and does it matter how hard and how long you run? I have read it with the care I give to anything that will shape how I guide you, and what follows is my honest reading of it, including the parts that are less reassuring than the headline. What the researchers did A meta-analysis does not run a new experiment. It gathers every study that has already asked a question, weighs each one by its size and quality, and pools the results into a single estimate that no individual study could reach on its own. The strength of the approach is scale; the weakness is that it inherits every flaw of the studies it pools. Keep both in mind as you read. The authors searched PubMed, Embase and the Cochrane Library through November 2016 and began with 1,907 references. After removing duplicates and discarding anything that was an animal study, an opinion piece, a review, or a study where neither the running nor the arthritis was clearly defined, they were left with 25 studies covering roughly 125,800 people. Seventeen of those, covering about 114,800 people, reported their numbers in a way that allowed pooling. The studies had to involve a physician-based diagnosis of hip or knee osteoarthritis, by examination or imaging. Pain alone, or a bone spur alone, did not count. The runners were sorted into two groups by the original authors’ own descriptions. Competitive runners were those reported as professional, elite, former elite, or international-level athletes, many of them Finnish Olympians and national champions from the 1920s to the 1960s who were followed for decades afterward. Recreational runners were everyone else who ran in a non-professional, amateur context. Controls were, in principle, sedentary non-runners, though as we will see, that principle held less firmly than the authors would have liked. They then asked three questions of the pooled data. Does the association with osteoarthritis differ between competitive and recreational runners? Does it differ for people who have run for less than fifteen years versus more? And does it change when studies account for the other things we already know drive joint degeneration, chiefly body weight, heavy physical labour, and previous joint injury? What they found The headline numbers are striking in their asymmetry. Among recreational runners, 3.5 percent had hip or knee osteoarthritis. Among the sedentary controls, the figure was 10.2 percent. Among competitive runners, it was 13.3 percent. The people who ran moderately had less joint disease than the people who did not run at all, and the people who ran at the highest level had the most of anyone. Prevalence figures of this kind need to be handled gently, because the groups were drawn from different studies with different ages, countries and eras, and a raw percentage does not account for any of that. The more useful comparison is the odds ratio, which compares each group of runners against the controls from its own study. Here the pattern held but softened. Recreational runners had roughly 14 percent lower odds of hip or knee osteoarthritis than controls, with a confidence interval that just crossed the line of no effect. For the knee alone, the protective association was slightly stronger and did clear that line. Competitive runners had about 34 percent higher odds than controls, again with an interval that brushed the null. The difference between the two groups of runners, however, was statistically clear, with a probability below one in a thousand of arising by chance. When the authors split the data by sex, the recreational advantage was most convincing in women, whose odds of hip or knee osteoarthritis were roughly half those of female controls. In men the reduction was smaller, around 22 percent, but the interval was narrow and did not cross the null. Competitive runners, whether male or female, consistently fared worse than their recreational counterparts. The overall prevalence of hip and knee osteoarthritis across all runners combined, competitive and recreational together, was 3.66 percent, against 10.23 percent in controls. Pooled this way, runners as a whole carried considerably less joint disease than people who did not run, because recreational runners vastly outnumber elite ones in the data, as they do in life. The fifteen-year threshold and the question of dose The finding most likely to be quoted at you is this one: people who had run for fewer than fifteen years had about 40 percent lower odds of hip or knee osteoarthritis than controls, while people who had run for more than fifteen years showed no difference from controls at all. Read quickly, it sounds like running protects you for a decade and a half and then begins to cost you. Read carefully, it says something narrower and more interesting. Every single study in the more-than-fifteen-years group involved competitive runners. Every study in the less-than-fifteen-years group involved recreational runners. The authors say this plainly: the two variables, duration and intensity, are completely entangled in the data, and there is no information at all on what happens to a recreational runner who keeps going for twenty or thirty years. The fifteen-year line is an artefact of which studies existed, not a biological threshold anyone measured. What the paper can say about dose comes from the individual studies rather than the pooled analysis. Danish orienteering runners covering 21 to 42 kilometres a week showed no excess hip or knee osteoarthritis compared with matched controls. Swiss former elite distance runners who had averaged 92 kilometres a week showed clearly more hip degeneration than controls, and notably, when the Swiss authors adjusted for mileage, the excess disappeared, which suggests the volume itself was carrying the risk rather than running as a category. A rat study the authors cite found cartilage protection at slight and moderate running distances that vanished at the longest distances. Rodent cartilage is not human cartilage, and I would not build a protocol on it, but the shape of the curve is consistent with what the human data hint at. The authors are honest that they could not establish a safe quantity of running for the hip and knee, because most studies either did not measure mileage or measured it in incompatible ways. They are equally honest that the labels competitive and recreational were assigned by the original researchers without any quantitative definition, so that a recreational runner in one study might out-train a competitive runner in another. What survives this uncertainty is the direction of the finding, not a number you could write on a training plan. What the evidence cannot tell us I would be doing you a disservice if I let the reassuring numbers stand without the weight the authors themselves placed on them. This is a level 2a study, which in the hierarchy of evidence sits below a randomised trial and above a single observational cohort. Of the 25 studies pooled, 18 were case-control or cross-sectional, meaning they looked at people at one moment and asked them to recall their running, rather than following them forward through time. The authors graded nearly every study as high risk for selection bias and performance bias, and for most of them the risk of other biases was simply unknown. Several of the key studies had fewer than fifty participants per group. The control groups were a persistent problem. The ideal comparison for a runner is a person who does nothing at all, and such people are hard to find and perhaps unethical to create. In practice, many controls walked, played other sports, or had run earlier in life, which blurs the contrast the study depends on. Some runners, in turn, also played tennis, skied, or competed in orienteering, so that the joint load being measured was not running alone. The deepest limitation is the one the authors return to repeatedly, and it is the one that matters most for how you should read the recreational finding. We know with reasonable confidence that three things drive osteoarthritis in weight-bearing joints: excess body weight, heavy occupational loading, and previous joint injury. Very few of the pooled studies adjusted for all three, and when the authors tried to compare adjusted against unadjusted studies, the sample thinned to the point where no clear pattern survived. It is entirely possible that recreational runners have healthier joints partly because they are, on average, leaner, less likely to work in heavy manual trades, and more likely to have avoided the knee injuries that would have ended a running habit. The study cannot separate the effect of running from the kind of person who keeps running, and the authors do not pretend otherwise. There is one modest exception. The two studies that adjusted for age, body mass, workload and prior injury all at once, both of which involved recreational runners, still found about 27 percent lower odds of hip or knee osteoarthritis in runners, with low heterogeneity between them. Two studies are not a verdict, but they point in the same direction as the whole. Finally, the search ended in November 2016, and the studies themselves span from 1975 to 2017. Only English-language work was included. Running shoes, training science, body composition and the way we diagnose osteoarthritis have all shifted over that span, and the Finnish Olympians who anchor the competitive data trained under conditions that bear little resemblance to a modern athlete’s. What this means for how you run I have spent years learning to hold two things at once: a genuine respect for what the evidence shows, and a refusal to claim more from it than it can bear. This paper rewards that posture. Here is how I read it into practice, with the confidence each point deserves. The fear that recreational running wears out healthy joints is not supported by the best pooled human data we have. Across more than a hundred thousand people, those who ran at an amateur level had less hip and knee osteoarthritis than those who did not run, and the pattern held across sexes and across the handful of studies that controlled for the strongest confounders. This is the paper’s most robust finding and the one I would lean on most. If you have been holding back from running out of concern for your knees, the weight of the evidence is on the side of running, and the authors themselves conclude that it can be safely recommended as a general health exercise. Cartilage is living tissue that adapts to load; it is nourished by the cycles of compression and release that walking and running provide, and the picture of a joint quietly grinding itself down with each stride does not match what the epidemiology shows. Volume and intensity appear to matter, and the elite data are a caution rather than a prohibition. Former Olympians and national-team distance runners, people who trained at mileages and intensities most of us will never approach, did carry more joint disease than the general population, and the one study that isolated mileage found that the excess tracked the kilometres. I take this as evidence for a dose curve: moderate loading that the tissue can recover from sits on the favourable side of it, and sustained very high loading over many years sits on the other. Where the inflection lies for any one person the paper cannot say, and I will not invent a number for you. What I can say is that the conditions under which running appears to turn against the joint are extreme, prolonged, and competitive, not the conditions of someone running three or four times a week for health. The three risk factors the authors kept returning to are the ones worth your attention. Body weight, heavy occupational loading, and previous joint injury each independently raise the risk of osteoarthritis, and the authors suspect that someone who begins running while carrying all three may be in a different position from the population in these studies. If you have a history of a serious knee or hip injury, a meniscus tear, a ligament reconstruction, or a labral repair, this paper does not reassure you specifically, because very few of its studies could account for that. It is the reason I ask about injury history before I ask about anything else, and the reason I would rather see someone with a surgical knee build toward running gradually and with attention than assume the population averages apply to them. And a note on what we do not know. No study in this analysis followed recreational runners past fifteen years. If you have been running for twenty-five years, or intend to, you are in territory the data have not mapped. I find that honest rather than frightening. The trajectory of the evidence, from the sedentary controls through the moderate runners, gives little reason to expect that someone who has run sensibly for a long time is accumulating hidden damage, but I will not tell you it has been measured when it has not. Observe your own joints carefully. Learn what the evidence can and cannot support. Adjust your running without ego when your body asks for it. That is the whole of my method, applied here as everywhere else. LAVV Sources: Alentorn-Geli E, Samuelsson K, Musahl V, Green CL, Bhandari M, Karlsson J. The Association of Recreational and Competitive Running With Hip and Knee Osteoarthritis: A Systematic Review and Meta-analysis. Journal of Orthopaedic and Sports Physical Therapy. 2017;47(6):373-390. doi:10.2519/jospt.2017.7137

Wonder how much AI is aiding in all these new drug discoveries...

Every few years in Korea, young adults walk into a clinic for a routine health screening. They are weighed, measured around the waist, asked about their habits, and sent home. For most of them the visit is forgettable. But because Korea keeps a single national health record for nearly everyone, those forgettable visits accumulate into something rare: a window onto the lives of millions of people, followed quietly across more than a decade. A study published this week in the Annals of Internal Medicine looked through that window. Researchers followed 6.3 million Koreans who were between 20 and 39 years old when they were first screened, none of whom had ever been diagnosed with cancer. Over an average of eleven years, about 152,000 of them developed one. The question was simple. Did the people who carried more weight in their twenties and thirties go on to develop cancer more often than those who did not? They did, and the pattern was steady. Among those of normal weight, roughly 1.84 in every 100 received a cancer diagnosis within ten years. Among those with what Korean guidelines call class I obesity, the figure rose to 2.24. Among those with class II obesity, it reached 2.62. These are Asian thresholds, worth noting, and they sit lower than the ones used in Europe and the Americas; class I obesity here begins at a body mass index of 25, a number many Western charts would still label as merely overweight. It is worth pausing on the size of those differences. The gap between normal weight and class II obesity, over ten years, was less than one additional case per hundred people. For any one person the shift in risk is modest. Spread across a nation of young adults, it becomes a great many diagnoses that might not otherwise have happened, and the authors found that the elevated risk did not fade as these people moved into their forties and fifties. What began in youth followed them into midlife. The more interesting finding, to my eye, had to do with the waist rather than the scale. When the researchers combined body mass index with waist circumference, a person with class I obesity who also carried abdominal fat had a higher ten-year cancer incidence than a person with class II obesity who did not. The heavier person with a leaner midsection fared better than the lighter person whose weight had settled around the organs. This echoes what we have long understood about visceral fat and its chemistry, the slow hum of inflammation and insulin signaling that seems to travel with it, and it suggests that a tape measure may sometimes tell a truer story than a scale. The cancers most strongly tied to weight were thyroid, endometrial, and ovarian. Men showed a sharper relative increase in risk, while women showed a larger absolute one, largely because the cancers most sensitive to excess weight in this age group live in the female reproductive system. Notably, obesity was not associated with breast cancer diagnosed before fifty, a finding consistent with earlier research showing that the relationship between weight and breast cancer changes direction after menopause. A few honest caveats belong here. This was an observational study, which means it can show that two things travel together but cannot prove that one caused the other. The people in it were those who chose to attend screening, which may make them somewhat different from the population at large. Smoking was not measured as finely as one would wish, and it shadows several of these cancers. Thyroid cancer in particular deserves a gentle asterisk, since Korea detects it at unusually high rates through ultrasound screening, and some of what is found may never have caused harm. And this is a Korean cohort, with Korean body composition and Korean definitions of obesity; the direction of the findings almost certainly travels, but the exact numbers may not. What remains, after the caveats, is a picture that is coherent with decades of prior work and sharpened by the youth of the people in it. The years between twenty and forty are often treated as a grace period, a stretch of life in which the body forgives most things. This study suggests the forgiveness is not complete. The weight a person carries in those years, and especially where they carry it, appears to leave a mark that persists long after. None of this calls for alarm. It calls for attention, paid early and paid to the right things: the circumference of the waist as much as the number on the scale, and the metabolic quiet that comes when both are kept in reasonable bounds. LAVV

Cult is gonna blame Biden anyways

We Venezuelans are forever grateful for the U.S. military intervention that permanently removed Maduro and Cilia. Yet, a rapid transition away from the current interim Chavista administration is critical. Only a legitimate democratic government can unlock the corporate and individual investment needed for Venezuela’s true and profound recovery. Hugo Chávez never drew crowds like this organically. @MariaCorinaYA’s leadership is indisputable, truly the most consequential force in 21st-century Latin America.

Here we go! 🇻🇪